Akın KAYA, Özgür KARACAN, Numan NUMANOĞLU, Ramazan İDİLMAN, İsmail SAVAŞ, Peri ARBAK

İdiopatik pulmoner fibrozis (12 olgu nedeni ile)

Kliniğimizde izlenen 12 İPF (İdiopatik Pulmoner Fibrozis) olgusu tanı ve tedavi yaklaşımı açısından retrospektif olarak değerlendirildi. Olguların yaş ortalaması 61.4 ± 14.3 ve erkek/kadın oranı bir idi. Yüksek rezolüsyonlu bilgisayarlı tomografi (YRBT) bulguları; 5 olguda (%41.7) interlobüler septal kalınlaşma; 2 olguda (%16.6) retikülonodüler patern, 5 olguda (%41.7) bal peteği paterni gözlendi. Solunum fonksiyon testlerinde restriktif patern gözlenirken, ortalama DLCO (% beklenen değer) %59.1 ± 32.9, alveolo-arteriyoler gradient ortalama 36.2 ± 18.3 bulundu. Tanı amaçlı bir olguya açık akciğer biyopsisi uygulanırken, 5 olguya TBAB uygulanmıştı. Üç hastada (%25) EBV IqG (+), 4 hastada (%33.3) CMV IgG (+), 2 hastada (%16.6) CMV IgM (+) bulundu. Tedavide steroidler ilk sırada yer alırken (%58.4), semptomatik tedavi (%25) ikinci sıradaydı. Serimizde yer alan 8 hastanın (%66.7) klinik seyrinin izlenemediği, 3 hastanın (%25.6) öldüğü gözlendi. Bulgular literatür bilgileri ile karşılaştırıldı.

Idiopathic pulmonary fibrosis (With 12 cases)

Twelve cases of idiopathic pulmonary fibrosis who had been hospitalized in our chest department evaluated for diagnostic and therapeutic management, retrospectively. Mean age was 61.4 ± 14.3 and male/female ratio was equal. Reticular pattern was observed on %41.7 of cases, reticulonodular pattern was observed on %16.6 of cases and honey-combing presented on %41.7 of cases on high-resolution computed tomography. Pulmonary function tests showed reticular pattern. While DLCO was %59.1 ± 32.9 (mean % predictive level), mean P (A-a) O2 was found as 36.2 ± 18.3. Open lung biopsy was used for one patient as a diagnostic approach, transbronchial biopsy was chosen for 5 patients. EBV IgG was found positive on 3 cases, four patients had positive results for CMV IgG, and two patients had positive results for CMV IgM, steroids were the first choise for treatment of %58.4 of the cases. Symptomatic therapy was used for three cases (%25), clinical course wasn't observed on eight of patients (%66.7). Three patients died (%25.6). Results were discussed.

PDF

___

1. Talmadge EK. Diagnostic Advances in Idiopathic Pulmonary Fibrosis, Chest 1991; 100: 238-41.
2. Mapel DW, Samet JM, Coultas DB. Corticosteroids and the Treatment of Idiopathic Pulmonary Fibrosis. Chest 1996; 110: 1058-67.
3. Reynolds HY. Diagnostic and management Strategies for Dissuse Interstitial Lung disease. Chest 1998; 113: 192-202.
4. Egan JJ, Woodcock AA, Stewart JP. Viruses and Idiopathic. Pulmonary Fibrosis, Eur Respir J 1997; 10: 1433-7.
5. Warwick MT. Interstitial Lung Disease of Unknown Etiology, Chest 1991; 100:232-3.
6. Mathieson JR, Mayo JR, Staples CA, et al. Chronic diffuse infiltrative lung disease: Comparison of diagnostic accuracy of CT and chest radiography Radiology 1983; 171: 111-6.
7. Line BR, Fulmer JD, Reynolds HY, et at. Gallium 67 citrate scanning in the staging of idiopathic pulmonary fibrosis: correlation with physiologic and morphologic features and brochoalveolar lavage,Am Rev Respir Dis 1978;118:355-65
8. Keogh BA, Crystal RG. Clinical significance of pulmonary function tests: Pulmonary function testing in interstitial pulmonary disease-what does it tell us? Chest 1980; 78: 856-65.
9. Watters LC, King TE, Schwarz Ml, et al. A clinical, radiographic and physiologic scoring system for the longitudinal assessment of patients with idiopathic pulmonary fibrosis. Am Rev Respir Dis 1986; 133: 97-103.
10. Karabıyıkoğlu G, Enacar N, Bartu S. Interstisyel Akciğer Fibrozisli vakalarımızdaki pulmoner Hipertansiyon Oranı; Tüberküloz ve Toraks 1986;34:81-7.
11. Johnston IDA, Gomn SA, Kalra S, et al. The management of cryptogenic Fibrosin alveolitis in three regions of the United Kingdom. Eur Respir J 1983; 6:891-3.
12. Veda T, Ohta K, Suzuki N, et al. Idiopathic pulmonary Fibrosis and high prevalence of serum antibodies to Hepatitits C Virüs. Am Rev Respir Dis 1992; 146:266-8.
13. Vergnon JM, Vincent M, De The G, et al. Crytogenic Fibrosing alveolitis and Epstein Barr virüs: an association Lancet 1984; 768-70.
14. Kuwano K, Nomuto Y, Kunitake R, et al. Defection of adenovirus EIA DNA in pulmonary fibrosis using nested polymerase chain reaction. Eur Respir J 1997; 10: 1445-9.
15. Lunch JP, McCune WJ. Immunosupressive and cytotoxic pharmacology for pulmonary disorders. Am J Respir Crit Care Med 1997; 155:395-420.
16. Douglas WW, Rya JH, Bjoraken JA, et al. Colchicine Therapy for idiopathic pulmonary fibrosis (abstract) Am Rev Respir Crit Care Med 1996; 153: 149.